ObsEva (MEX:OBSN N) Debt-to-EBITDA : (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:OBSN N ObsEva SA MEX:OBSN N
18 GF Score
Price MXN1.70
View Full Analysis

What is ObsEva Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

ObsEva's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was MXN59.0 Mil. ObsEva's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was MXN0.0 Mil. ObsEva's annualized EBITDA for the quarter that ended in Dec. 2022 was MXN2,568.8 Mil. ObsEva's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 was 0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for ObsEva's Debt-to-EBITDA or its related term are showing as below:

MEX:OBSN N's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.215
* Ranked among companies with meaningful Debt-to-EBITDA only.

ObsEva  (MEX:OBSN N) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

ObsEva Debt-to-EBITDA Related Terms

ObsEva Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for ObsEva's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ObsEva Debt-to-EBITDA Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only - - - - -

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:OBSN N vs VRTX, REGN, SGEN: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, ObsEva's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ObsEva Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where ObsEva's Debt-to-EBITDA falls into.


MEX:OBSN N
18GF Score
ObsEva SA MEX:OBSN N
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ObsEva Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

ObsEva's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(58.98790575 + 0) / -403.93394668232
=-0.15

ObsEva's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(58.98790575 + 0) / 2568.8150337347
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2022) EBITDA data.

ObsEva Business Description

Address Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
18GF Score

Get the complete analysis for MEX:OBSN N

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1.70
Price